Commitments and Contingencies - Quimilza - Narrative (Details) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended		9 Months Ended		12 Months Ended
	Jan. 31, 2025	Sep. 30, 2026	Sep. 30, 2025	Sep. 30, 2026	Sep. 30, 2025	Dec. 31, 2025
Commitments and Contingencies [Line Items]
Research and development		$ 27,622	$ 22,563	$ 93,010	$ 80,265
Quimilza
Commitments and Contingencies [Line Items]
Development and milestone obligations paid to third party	$ 10,000
Additional development and milestone payments to third party	$ 5,000
Research and development						$ 14,400
Royalty payable on net sales (in percent)	10.00%
Quimilza \| Future Regulatory Approval and Sales Milestones
Commitments and Contingencies [Line Items]
Possible future milestone payment				35,000
Quimilza \| Future Regulatory Approval, Filing Application For Marketing Authorization Milestone \| U.S.
Commitments and Contingencies [Line Items]
Possible future milestone payment				5,000
Quimilza \| Future Regulatory Approval, Filing Application For Marketing Authorization Milestone \| E.U.
Commitments and Contingencies [Line Items]
Possible future milestone payment				5,000
Quimilza \| Future Regulatory Approval, Sales Milestones
Commitments and Contingencies [Line Items]
Possible future milestone payment				$ 25,000